Skip to main content
    E

    Exagen Inc (XGN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $3.77
    -0.36 (-8.72%)

    Market Cap: $105.37M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Exagen Inc (XGN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Exagen reported revenue of $66.58M for the fiscal year ended Dec 31, 2025, up 19.7% from the year before. That year, net income was -$19.95M with a net margin of -30.0%, operating cash flow was -$13.63M and free cash flow was -$14.27M. The quarter ended Sep 30, 2026 had revenue of $18.42M and net income of -$6.34M.

    Revenue and Margins

    The operating margin was -21.1% in the fiscal year ended Dec 2025. Over the 10 years to Dec 2025, revenue grew from $17.95M, a compound annual rate of 14.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$66.58M+19.7%58.3%-21.1%-30.0%
    Dec 2024$55.64M+5.9%59.5%-24.5%-27.2%
    Dec 2023$52.55M+15.3%56.1%-43.5%-45.1%
    Dec 2022$45.56M-5.7%46.9%-101.1%-104.0%
    Dec 2021$48.30M+15.1%57.4%-49.8%-55.6%
    Dec 2020$41.98M+3.9%60.6%-36.2%-39.8%
    Dec 2019$40.39M+24.5%53.4%-23.0%-29.8%
    Dec 2018$32.44M+21.0%52.6%-15.0%-24.7%
    Dec 2017$26.81MN/A47.3%-29.2%-95.6%
    Dec 2015$17.95MN/A46.9%-57.9%-106.9%
    Annual, fiscal years ended Dec 2015 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2015
    Revenue$66.58M$55.64M$52.55M$45.56M$48.30M$41.98M$40.39M$32.44M$26.81M$17.95M
    Cost of revenue$27.78M$22.53M$23.09M$24.21M$20.59M$16.56M$18.81M$15.38M$14.14M$9.53M
    Gross profit$38.80M$33.11M$29.46M$21.35M$27.71M$25.42M$21.58M$17.06M$12.67M$8.41M
    Research and development$6.25M$5.38M$4.87M$9.88M$7.24M$3.57M$2.18M$2.13M$1.55M$1.37M
    Operating income-$14.07M-$13.64M-$22.84M-$46.05M-$24.07M-$15.19M-$9.30M-$4.88M-$7.84M-$10.39M
    Net income-$19.95M-$15.12M-$23.69M-$47.39M-$26.85M-$16.69M-$12.04M-$8.01M-$25.63M-$19.18M
    EBITDA-$12.34M-$11.76M-$20.51M-$44.33M-$22.84M-$13.38M-$7.24M-$4.36MN/AN/A
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$18.42M$19.94M$17.31M$16.63M$17.24M$17.20M$15.50M$13.65M$12.51M$15.06M$14.41M$13.77M
    Gross profit$10.84M$12.22M$10.21M$9.21M$10.07M$10.39M$9.12M$8.48M$6.98M$9.06M$8.60M$8.14M
    Operating income-$4.41M-$1.72M-$3.41M-$4.97M-$3.10M-$2.63M-$3.37M-$3.38M-$4.66M-$2.59M-$3.00M-$5.15M
    Net income-$6.34M-$3.20M-$3.97M-$4.67M-$7.09M-$4.44M-$3.75M-$3.76M-$5.03M-$2.97M-$3.36M-$5.57M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $22.91M by $9.31M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2015
    Total assets$58.02M$44.69M$56.94M$86.22M$123.44M$78.38M$88.31M$28.89M$20.39M$14.63M
    Current assets$48.89M$36.45M$47.84M$72.61M$112.73M$70.52M$81.25M$21.31M$13.26M$3.87M
    Cash and equivalents$32.22M$22.04M$36.49M$62.39M$99.44M$57.45M$72.08M$13.16M$11.24M$2.51M
    Total liabilities$40.57M$35.15M$34.25M$43.76M$38.51M$36.54M$32.65M$35.62M$25.03M$36.81M
    Short-term debt$643.00K$423.00K$264.00K$190.00K$0$308.00K$238.00K$81.00K$27.00K$25.90M
    Long-term debt$22.26M$19.82M$19.23M$28.78M$27.48M$26.66M$25.85M$24.62M$18.81M$0
    Shareholder equity$17.45M$9.54M$22.69M$42.46M$84.94M$41.84M$55.66M-$111.97M-$4.64M-$22.18M
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$55.35M$51.94M$51.96M$58.02M$62.82M$58.76M$40.29M$44.69M$43.60M$49.31M$50.81M$56.94M
    Total liabilities$41.58M$39.72M$37.52M$40.57M$44.69M$37.73M$33.89M$35.15M$30.74M$31.72M$30.82M$34.25M
    Cash and equivalents$28.09M$24.59M$21.51M$32.22M$35.65M$30.03M$11.19M$22.04M$22.04M$24.48M$27.27M$36.49M
    Shareholder equity$13.78M$12.22M$14.43M$17.45M$18.14M$21.03M$6.40M$9.54M$12.87M$17.59M$19.99M$22.69M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2015
    Operating cash flow-$13.63M-$13.28M-$14.46M-$32.14M-$20.27M-$14.08M-$9.71M-$9.30M-$10.97M-$11.90M
    Capital expenditures$641.00K$515.00K$828.00K$4.32M$2.42M$455.00K$403.00K$199.00K$567.00K$805.00K
    Free cash flow-$14.27M-$13.79M-$15.29M-$36.46M-$22.69M-$14.54M-$10.11M-$9.50M-$11.54M-$12.71M
    Dividends paidN/AN/A$9.94MN/A$390.00K$142.00K$6.74M$0$0$0
    Share repurchasesN/AN/AN/AN/A$4.45M$21.00K$0N/AN/AN/A
    Investing cash flow-$626.00K-$515.00K-$804.00K-$4.32M-$2.42M-$455.00K-$103.00K-$199.00K-$510.00K-$800.00K
    Financing cash flow$24.43M-$663.00K-$10.63M-$489.00K$64.68M-$97.00K$68.73M$11.42M$19.16M$10.61M
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.58M$3.99M-$10.42M-$3.01M$2.94M-$2.88M-$10.67M$363.00K-$2.18M-$2.43M-$9.04M$8.35M
    Capital expenditures$196.00K$543.00K$228.00K$44.00K$275.00K$209.00K$113.00K$146.00K$147.00K$136.00K$86.00K$106.00K
    Free cash flow-$2.77M$3.44M-$10.64M-$3.06M$2.67M-$3.09M-$10.78M$217.00K-$2.32M-$2.56M-$9.13M$8.24M
    Last 12 quarters

    Frequently Asked Questions About XGN

    What is Exagen's annual revenue?

    Exagen reported revenue of $66.58M for the fiscal year ended Dec 31, 2025.

    How fast is Exagen's revenue growing?

    Revenue was up 19.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 13.5%.

    Is Exagen profitable?

    No. Exagen reported net income of -$19.95M for the fiscal year ended Dec 31, 2025, with a net margin of -30.0%.

    How much free cash flow does XGN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.63M minus capital expenditures of $641.00K produced free cash flow of -$14.27M.

    How much debt does Exagen have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $22.26M, short-term debt of $643.00K and cash and equivalents of $32.22M.